<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02026128</url>
  </required_header>
  <id_info>
    <org_study_id>OHSU IRB#00008052</org_study_id>
    <nct_id>NCT02026128</nct_id>
  </id_info>
  <brief_title>Optical Coherence Tomography (OCT) in Uveitis</brief_title>
  <official_title>Objective Grading of Intraocular Inflammation in Uveitis Using Optical Coherence Tomography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Optical Coherence Tomography (OCT) machines are non-contact instruments that can provide&#xD;
      micrometer (one one-thousandths) scale imaging of biological tissue. This allows excellent&#xD;
      assessment of the white blood and inflammatory cells seen in uveitis, an inflammation of any&#xD;
      or all parts of the uvea (iris, ciliary body, choroid).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In uveitis, white blood and inflammatory cells can enter the anterior chamber of the eye and&#xD;
      adhere to the back surface of the cornea or enter the space between the lens and the retina&#xD;
      in various types of uveitis. Transparency of the clear fluid that fills the space between the&#xD;
      cornea and the lens (or between the lens and the retina) can be reduced due to the&#xD;
      inflammation reaction of the eye. The amounts of these cells and reduced transparency that&#xD;
      are present indicate the level of severity of inflammation.&#xD;
&#xD;
      The primary goal of this study is to use OCT to standardize anterior chamber (AC) cell&#xD;
      grading. Another goal is to discover whether the size of cells and particles in the AC&#xD;
      measured by OCT differs between uveitis diagnostic categories. OCT will also be used to&#xD;
      detect protein concentration increases within the clear fluid inside the eye and determine if&#xD;
      the concentration increase correlates with findings from the usual slit lamp grading method.&#xD;
&#xD;
      Background data including age, sex, medical history, and eye history will be gathered prior&#xD;
      to the study/OCT testing visit. Other standard-of-care testing, like visual acuity and slit&#xD;
      lamp (biomicroscope) exam will be performed to see if there is evidence of uveitis that meets&#xD;
      the inclusion criteria for this study. If so, grading of the eye inflammation will be&#xD;
      performed as defined by the Standardization of Uveitis Nomenclature (SUN). Once enrolled in&#xD;
      the study, subjects will then undergo OCT testing with the study device to assess AC cells,&#xD;
      AC flare (increased protein), keratic precipitates (cells adhered to back surface of cornea),&#xD;
      and vitreous cells &amp; haze (increased opacities in vitreous gel).&#xD;
&#xD;
      OCT Procedure: The subject will be seated and have their head positioned on a chin rest. They&#xD;
      will be asked to look at a target (a lighted spot) while a beam of light scans the front part&#xD;
      of the eye. The light is infrared and will not be visible or cause any sensation. A cotton&#xD;
      tip swab may be used to help hold the eyelid open temporarily if necessary.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of anterior chamber cells</measure>
    <time_frame>1 month</time_frame>
    <description>Anterior chamber cells will be identified from OCT images by computer algorithms. Anterior chamber cells will be measured in particles.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of keratic precipitates (KP)</measure>
    <time_frame>1 month</time_frame>
    <description>KPs will be identified from OCT images by computer algorithms. KPs will be measured in particles.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of vitreous cells</measure>
    <time_frame>1 month</time_frame>
    <description>Vitreous cells will be identified from OCT images by computer algorithms. Vitreous cells will be measured in particles.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Degree of anterior chamber flare</measure>
    <time_frame>1 month</time_frame>
    <description>OCT signal of the aqueous humor will be analyzed and correlated with slit lamp grades on AC flare. AC flare will be measured in a.u.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Uveitis</condition>
  <arm_group>
    <arm_group_label>Active Uveitis</arm_group_label>
    <description>Physician-confirmed diagnosis of uveitis of any origin.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The study will enroll both males and females and include all ethnic and racial groups&#xD;
        through clinical practices. The study will enroll subjects 18 years of age or older with&#xD;
        physician-confirmed, active uveitis. A total of thirty subjects will be recruited.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age and older&#xD;
&#xD;
          -  With one or more of the following clinical features:&#xD;
&#xD;
               1. &gt;1+ AC cells;&#xD;
&#xD;
               2. &gt;1+ vitreous haze;&#xD;
&#xD;
               3. presence of vitreous cells;&#xD;
&#xD;
               4. presence of blood in anterior chamber;&#xD;
&#xD;
               5. presence of blood in vitreous;&#xD;
&#xD;
               6. presence of aqueous or vitreous pigment.&#xD;
&#xD;
          -  In one of the following diagnostic categories as determined by a uveitis specialists:&#xD;
&#xD;
               1. uveitis due to ankylosing spondylitis (positive HLA B27 genotype);&#xD;
&#xD;
               2. uveitis due to sarcoidosis;&#xD;
&#xD;
               3. uveitis of any additional type;&#xD;
&#xD;
               4. uveitis masquerade such as pigment dispersion syndrome or Schaffer's sign;&#xD;
&#xD;
               5. hyphema due to trauma or other causes;&#xD;
&#xD;
               6. vitreous hemorrhage;&#xD;
&#xD;
               7. retinal tear.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to give informed consent;&#xD;
&#xD;
          -  Inability to maintain stable fixation for OCT imaging.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Rosenbaum, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Denny Romfh, OD</last_name>
    <phone>503-494-4351</phone>
    <email>romfhd@ohsu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Humberto Martinez, COT</last_name>
    <phone>503-494-7712</phone>
    <email>martinhu@ohsu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denny Romfh, OD</last_name>
      <phone>503-494-4351</phone>
      <email>romfhd@ohsu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Humberto Martinez, COT</last_name>
      <phone>503-494-7712</phone>
      <email>martinhu@ohsu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Eric Suhler, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Huang, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Phoebe Lin, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yan Li, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 30, 2013</study_first_submitted>
  <study_first_submitted_qc>December 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2014</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>David Huang</investigator_full_name>
    <investigator_title>James Rosenbaum, MD, Director, Uveitis Clinic, Casey Eye Institute; Chief, Division of Arthritis &amp; Rheumatic Diseases, OHSU; Vice-Chair, Casey Eye Institute; Professor of Ophthalmology, Medicine and Cell Biology, OHSU</investigator_title>
  </responsible_party>
  <keyword>Uveitis</keyword>
  <keyword>Inflammation</keyword>
  <keyword>OCT</keyword>
  <keyword>Grading</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uveitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

